The UK and US have hammered out a significant commercial pact that will maintain no levies on British pharmaceutical exports going into the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these key products will remain at zero for a duration of the next three years.
This agreement comes after earlier warnings to dramatically increase import taxes on patented pharmaceutical products, with figures mentioned up to double the cost.
"This agreement between the Britain strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue equity to American-British pharmaceutical trade," a release said.
Economic Significance
Medicines represent one of the Britain's biggest export categories to the United States, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that timeframe.
"This deal protects jobs, increases capital expenditure and facilitates the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The deal entails several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to increase overall NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped 20%.
Industry Background
This agreement comes amid a long-running dispute between the sector and the ministers over drug pricing and regulatory access.
The disagreement were heightened by arguments that US customers were charged significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several large drug company projects in the UK have been halted or abandoned, while major expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the previous ten-year period.
